Abstract
Dendritic cells can be derived from leukemia cells and normal precursor cells in the patients with acute myeloid leukemia (AML). Dendritic cells may capture leukemia antigen in bone marrow or lymph nodes, and present leukemia common antigen to stimulate proliferation of specific CD8(+) T cells, playing anti-leukemia effect. Dendritic cells for clinical and experimental use are transformed from leukemia cells and peripheral blood mononuclear cells and loaded in vitro with leukemia -specific or tumor common antigen, play a therapeutic role after reinfusion. This article reviews dendritic cells in the immunotherapy of AML.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
